Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

c-Myc and downstream targets in the pathogenesis and treatment of cancer

Tools
- Tools
+ Tools

Robson, Samuel Charles, Pelengaris, Stella and Khan, Michael (2006) c-Myc and downstream targets in the pathogenesis and treatment of cancer. Recent Patents on Anti-Cancer Drug Discovery, Vol.1 (No.3). pp. 305-326. doi:10.2174/157489206778776934

Research output not available from this repository, contact author.
Official URL: http://www.benthamscience.com/contents-JCode-PRA-V...

Request Changes to record.

Abstract

The c-Myc oncoprotein is a master regulator of genes involved in diverse cellular processes. Situated upstream of signalling pathways regulating cellular replication/growth as well as apoptosis/growth arrest, c-Myc may help integrate processes determining cell numbers and tissue size in physiology and disease. In cancer, this 'dual potential' allows cMyc to act as its own tumour suppressor. Evidently, given that deregulated expression of c-Myc is present in most, if not all, human cancers (Table 1) and is associated with a poor prognosis, by implication these in-built 'failsafe' mechanisms have been overcome.

To explore the complex activity of c-Myc and its potential as a therapeutic target 'post-genome era' technologies for determining global gene expression alongside advanced new models for the study of tumourigenesis in vivo have proved invaluable. Thus, many recent studies have provided encouragement for the therapeutic targeting of c-Myc in cancer and have revealed new protein targets for manipulating aspects of c-Myc activity. The remarkable regression of even advanced and genetically unstable tumours, seen following deactivation of c-Myc in various models is particularly exciting.

This review will discuss what is known about the role of c-Myc in growth deregulation and cancer and will conclude with a discussion of the most promising recent developments in Myc-targeted therapeutics.

Item Type: Journal Item
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
R Medicine > RS Pharmacy and materia medica
Divisions: Faculty of Science, Engineering and Medicine > Science > Life Sciences (2010- )
Journal or Publication Title: Recent Patents on Anti-Cancer Drug Discovery
Publisher: Bentham Science Publishers Ltd.
ISSN: 1574-8928
Official Date: November 2006
Dates:
DateEvent
November 2006Published
Volume: Vol.1
Number: No.3
Number of Pages: 22
Page Range: pp. 305-326
DOI: 10.2174/157489206778776934
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Restricted or Subscription Access
Related URLs:
  • Publisher

Data sourced from Thomson Reuters' Web of Knowledge

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item
twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us